Skip to main content

Cancer Immunology, Immunotherapy

Ausgabe 7/2022

Inhalt (20 Artikel)

Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy

  • Review Article

Chuan Liu, Guangwei Zhang, Kanghui Xiang, Yohan Kim, Roxane R. Lavoie, Fabrice Lucien, Ti Wen

Identification of HLA-A2 restricted epitopes of glypican-3 and induction of CTL responses in HLA-A2 transgenic mice

  • Original Article

Xiaoxiao Jin, Xiaotao Liu, Zining Zhou, Yan Ding, Yandan Wu, Jie Qiu, Chuanlai Shen

TGF-β orchestrates the phenotype and function of monocytic myeloid-derived suppressor cells in colorectal cancer

  • Open Access
  • Original Article

Luciana Gneo, Nagy Rizkalla, Rahul Hejmadi, Francis Mussai, Carmela de Santo, Gary Middleton

Robust immune response stimulated by in situ injection of CpG/αOX40/cGAMP in αPD-1-resistant malignancy

  • Open Access
  • Original Article

Luya Cai, Xuedan Du, Cheng Zhang, Shanshan Yu, Lixiao Liu, Jinduo Zhao, Ye Zhao, Chunhong Zhang, Jinting Wu, Bin Wang, Yingyu Chen, Xiaoping Su, Xiaojian Yan, Wenfeng Li

Redirecting host preexisting influenza A virus immunity for cancer immunotherapy

  • Original Article

Bharat K. R. Chaganty, Songbo Qiu, Yang Lu, Gabriel Lopez-Berestein, Bulent Ozpolat, Zhen Fan

Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study

  • Original Article

Xiangling Chu, Huiping Qiang, Mengqing Xie, Xing Li, Jing Zhao, Yan Wu, Juan Zhou, Jinyan Ye, Chao Zhao, Chaonan Han, Tianqing Chu, Chunxia Su

Prognostic value of soluble programmed cell death-1 (sPD-1) and soluble programmed cell death ligand-1 (sPD-L1) for hepatocellular carcinoma: a systematic review and meta-analysis

  • Original Article

Jun-shuai Xue, Hui Liu, Guang-Xiao Meng, Zi-Niu Ding, Lun-Jie Yan, Sheng-Yu Yao, Hai-Chao Li, Zhao-Ru Dong, Zhi-Qiang Chen, Jian-Guo Hong, Tao Li

Distribution, phenotype, functional and clinical relevance of CD8+CD103+ tissue-resident memory T cells in human gastric cancer

  • Original Article

Yang Shen, Xiao-long Li, Yu-xian Li, Zhi-guo Shan, Yong-liang Zhao, Ping Cheng, Zhuo Zhao, Jin-yu Zhang, Weisan Chen, Yuan Zhuang, Dai-yuan Ma, Quan-ming Zou, Yuan Qiu, Liu-sheng Peng

Endoplasmic reticulum stress-induced release and binding of calreticulin from human ovarian cancer cells

  • Open Access
  • Original Article

Trefa M. Abdullah, Jacqueline Whatmore, Edwin Bremer, Rimantas Slibinskas, Marek Michalak, Paul Eggleton

Chemical screening identifies novel small molecule activators of natural killer cell cytotoxicity against cancer cells

  • Original Article

Grace Lee, Sheela Karunanithi, Bruce Posner, Hanspeter Niederstrasser, Hong Cheng, Yuriy Federov, Shivaprasad Manjappa, Karam Musaitif, Huaiyu Wang, Zachary Jackson, David Wald

Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy

  • Original Article

Qiaoyun Tan, Liyuan Dai, Yanrong Wang, Shuxia Liu, Te Liang, Rongrong Luo, Shasha Wang, Ning Lou, Haizhu Chen, Yu Zhou, Qiaofeng Zhong, Jianliang Yang, Puyuan Xing, Xingsheng Hu, Yutao Liu, Shengyu Zhou, Jiarui Yao, Di Wu, Zhishang Zhang, Le Tang, Xiaobo Yu, Xiaohong Han, Yuankai Shi

The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study

  • Original Article

Wenxian Wang, Xiaodong Gu, Liping Wang, Xingxiang Pu, Huijing Feng, Chunwei Xu, Guangyuan Lou, Lan Shao, Yibing Xu, Qian Wang, Siyuan Wang, Wenbin Gao, Yiping Zhang, Zhengbo Song

Blood DCs activated with R848 and poly(I:C) induce antigen-specific immune responses against viral and tumor-associated antigens

  • Open Access
  • Original Article

Gerulf Hänel, Caroline Angerer, Katja Petry, Felix S. Lichtenegger, Marion Subklewe

Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study

  • Original Article

Geoffroy Bilger, Nicolas Girard, Hélène Doubre, Matteo Giaj Levra, Etienne Giroux-Leprieur, Frederique Giraud, Chantal Decroisette, Matthieu Carton, Marie Ange Massiani

Metformin inhibits human non-small cell lung cancer by regulating AMPK–CEBPB–PDL1 signaling pathway

  • Original Article

Tao Lu, Ming Li, Mengnan Zhao, Yiwei Huang, Guoshu Bi, Jiaqi Liang, Zhencong Chen, Yuansheng Zheng, Junjie Xi, Zongwu Lin, Cheng Zhan, Wei Jiang, Qun Wang, Lijie Tan

Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab

  • Original Article

Mathilde Bureau, Thierry Chatellier, Tanguy Perennec, Thomas Goronflot, Charlotte Greilsamer, Anne-Laure Chene, Raafet Affi, Eric Frampas, Jaafar Bennouna, Elvire Pons-Tostivint

Efficient adoptive transfer of autologous modified B cells: a new humanized platform mouse model for testing B cells reprogramming therapies

  • Open Access
  • Research Report

Audrey Page, Emilie Laurent, Didier Nègre, Caroline Costa, Véronique Pierre, Thierry Defrance, François-Loïc Cosset, Floriane Fusil

Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11–13 2019, Verona, Italy

  • Letter to the Editors

Matteo Bellone, Marco Bregni, Vincenzo Bronte, Stefano Ugel, Pier Francesco Ferrucci, Massimo Di Nicola, Paola Nisticò, Gaia Zuccolotto, Antonio Rosato, Vincenzo Russo, Antonio Sica, Mario P. Colombo

Cancer bio-immunotherapy XVIII annual NIBIT-(Italian network for tumor biotherapy) meeting, October 15–16, 2020

  • Letter to the Editors

Matteo Bellone, Arianna Brevi, Vincenzo Bronte, Silvia Dusi, Pier Francesco Ferrucci, Paola Nisticò, Antonio Rosato, Vincenzo Russo, Antonio Sica, Gabriele Toietta, Mario Paolo Colombo

Neu im Fachgebiet Onkologie

Bald 5% der Krebserkrankungen durch CT verursacht

Die jährlich rund 93 Millionen CTs in den USA könnten künftig zu über 100.000 zusätzlichen Krebserkrankungen führen, geht aus einer Modellrechnung hervor. Damit würde eine von 20 Krebserkrankungen auf die ionisierende Strahlung bei CT-Untersuchungen zurückgehen.

Weniger aggressive Prostatakrebs-Therapie, gleiche Prognose

Erhalten ältere Prostatakrebs-Patienten vor Therapiebeginn ein geriatrisches Assessment, führt dies häufig zu einer Deeskalation der Behandlung – ohne dass ihre Prognose dadurch schlechter würde. Darauf deuten Erfahrungen aus Frankreich hin. 

Nach kardiovaskulärer Erkrankung steigt das Krebsrisiko

Wer an einer kardiovaskulären Erkrankung (CVD) leidet, hat offenbar ein erhöhtes Risiko, in der Folge auch noch eine Krebsdiagnose zu erhalten. Der Zusammenhang scheint für diverse CVD und Krebsentitäten zu gelten.

Fortgeschrittenes Melanom: Wann den Checkpoint-Inhibitor absetzen?

Eine ICI-Therapie sollte bei Betroffenen mit fortgeschrittenem Melanom mindestens ein Jahr fortgesetzt werden. Bei anhaltendem Ansprechen kann danach offenbar ohne hohes Risiko ein Therapieabbruch erwogen werden.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.